Truist Financial Corp Has $1.27 Million Stock Position in BioNTech SE (NASDAQ:BNTX)

Truist Financial Corp lowered its position in shares of BioNTech SE (NASDAQ:BNTX) by 4.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,784 shares of the company’s stock after selling 678 shares during the quarter. Truist Financial Corp’s holdings in BioNTech were worth $1,268,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of BNTX. Virtu Financial LLC acquired a new position in BioNTech during the 4th quarter worth approximately $274,000. Goldman Sachs Group Inc. boosted its holdings in shares of BioNTech by 17.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 182,878 shares of the company’s stock valued at $19,301,000 after buying an additional 26,777 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of BioNTech by 207.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,583 shares of the company’s stock valued at $273,000 after buying an additional 1,743 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of BioNTech by 121.0% in the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after buying an additional 150 shares during the last quarter. Finally, Green Alpha Advisors LLC boosted its holdings in shares of BioNTech by 12.9% in the 1st quarter. Green Alpha Advisors LLC now owns 5,819 shares of the company’s stock valued at $537,000 after buying an additional 666 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

Wall Street Analysts Forecast Growth

BNTX has been the subject of several recent analyst reports. UBS Group increased their price objective on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a report on Wednesday, September 18th. Bank of America increased their price objective on BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a report on Monday, September 16th. Hsbc Global Res raised BioNTech from a “hold” rating to a “strong-buy” rating in a report on Friday, August 2nd. TD Cowen cut their price objective on BioNTech from $98.00 to $85.00 and set a “hold” rating for the company in a report on Tuesday, August 6th. Finally, Morgan Stanley raised BioNTech from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $93.00 to $145.00 in a report on Tuesday, September 24th. Five research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.92.

BioNTech Stock Up 1.8 %

BNTX opened at $120.52 on Friday. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54. The company has a market capitalization of $28.66 billion, a P/E ratio of -53.33 and a beta of 0.24. The stock has a fifty day moving average of $100.90 and a 200-day moving average of $93.36.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The firm had revenue of $128.70 million for the quarter, compared to analyst estimates of $134.98 million. During the same period in the prior year, the business posted ($0.86) EPS. The firm’s quarterly revenue was down 23.3% compared to the same quarter last year. On average, equities analysts expect that BioNTech SE will post -3.04 EPS for the current year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.